The dual role of Nrf2 in nonalcoholic fatty liver disease: Regulation of antioxidant defenses and hepatic lipid metabolism

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Chambel, Sílvia S ^a,b   Santos Gonçalves, Andreia ^a,b   Duarte, Tiago L ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; FATTY ACID; NFE2L2 PROTEIN, HUMAN;

AGING; ARTICLE; HUMAN; LIPID METABOLISM; LIVER INJURY; LIVER METABOLISM; LIVER PROTECTION; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; PREVALENCE; PROTEIN FUNCTION; PROTEIN TARGETING; BIOSYNTHESIS; GENETICS; LIVER; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALIA; RODENTIA;

ANTIOXIDANTS; FATTY ACIDS; HUMANS; LIPID METABOLISM; LIVER; NF-E2-RELATED FACTOR 2; NON-ALCOHOLIC FATTY LIVER DISEASE; REACTIVE OXYGEN SPECIES;

EID: 84930625964     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/597134     Document Type: Article

References (86)

1. J. Huang, J. Borensztajn, and J. K. Reddy, "Hepatic lipid metabolism," in Molecular Pathology of Liver Diseases, S. P. S. Monga, Ed., vol. 5, pp. 133-146, Springer, Berlin, Germany, 2011.
2. G. Serviddio, F. Bellanti, and G. Vendemiale, "Free radical biology for medicine: learning from nonalcoholic fatty liver disease,"FreeRadical BiologyandMedicine, vol. 65,pp. 952-968, 2013.
3. Y. SteinandB. Shapiro, "Uptake andmetabolismof triglycerides by the rat liver," Journal of Lipid Research, vol. 1, pp. 326-331, 1960.
4. K. Liu and M. J. Czaja, "Regulation of lipid stores and metabolism by lipophagy," Cell Death and Differentiation, vol. 20, no. 1, pp. 3-11, 2013.
5. V. Zámbó, L. Simon-Szabó, P. Szelényi, é. Kereszturi, G. Bánhegyi, and M. Csala, "Lipotoxicity in the liver," World Journal of Hepatology, vol. 5, no. 10, pp. 550-557, 2013.
6. E. L. Seifert, C. Estey, J. Y. Xuan, and M.-E. Harper, "Electron transport chain-dependent and-independent mechanisms of mitochondrial H2O2 emission during long-chain fatty acid oxidation," The Journal of Biological Chemistry, vol. 285, no. 8, pp. 5748-5758, 2010.
7. G. Vial, H. Dubouchaud, K. Couturier et al., "Effects of a highfat diet on energy metabolism and ROS production in rat liver," Journal of Hepatology, vol. 54, no. 2, pp. 348-356, 2011.
8. A. K. Leamy, R. A. Egnatchik, and J. D. Young, "Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease," Progress in Lipid Research, vol. 52, no. 1, pp. 165-174, 2013.
9. E. S. Ford, W. H. Giles, and W. H. Dietz, "Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey," The Journal of the American Medical Association, vol. 287, no. 3, pp. 356-359, 2002.
10. D. M. Boudreau, D. C. Malone, M. A. Raebel et al., "Health care utilization and costs by metabolic syndrome risk factors," Metabolic Syndrome andRelatedDisorders, vol. 7, no. 4, pp. 305-313, 2009.
11. K. G. M. M. Alberti, P. Zimmet, and J. Shaw, "Metabolic syndrome-A new world-wide definition. A Consensus Statement from the International Diabetes Federation," Diabetic Medicine, vol. 23, no. 5, pp. 469-480, 2006.
12. P. Dietrich and C. Hellerbrand, "Non-alcoholic fatty liver disease, obesity and the metabolic syndrome," Best Practice & Research Clinical Gastroenterology, vol. 28, no. 4, pp. 637-653, 2014.
13. K. I. Tong,A.Kobayashi,F.Katsuoka, andM.Yamamoto, "Twosite substrate recognition model for the Keap1-Nrf2 system: A hinge and latch mechanism," The Journal of Biological Chemistry, vol. 387, no. 10-11, pp. 1311-1320, 2006.
14. C. P. Day and O. F. W. James, "Hepatic steatosis: innocent bystander or guilty party?" Hepatology, vol. 27, no. 6, pp. 1463-1466, 1998.
15. S.-J. Lee, J. Zhang, A. M. K. Choi, and H. P. Kim, "Mitochondrial dysfunction induces formation of lipid droplets as a generalized response to stress," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID327167, 10 pages, 2013.
16. M.Amir andM. J. Czaja, "Autophagy innonalcoholic steatohepatitis," Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 159-166, 2011.
17. Z. Tariq, C. J. Green, and L. Hodson, "Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?" Liver International, vol. 34,no. 7, pp. e180-e190, 2014.
18. Y.-K. J. Zhang, R. L. Yeager, Y. Tanaka, and C. D. Klaassen, "Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine-and choline-deficient diet," Toxicology and Applied Pharmacology, vol. 245, no. 3, pp. 326-334, 2010.
19. M. S. Yates, Q. T. Tran, P. M. Dolan et al., "Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice," Carcinogenesis, vol. 30, no. 6, pp. 1024-1031, 2009.
20. N. R. Kitteringham, A. Abdullah, J. Walsh et al., "Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver," Journal of Proteomics, vol. 73, no. 8, pp. 1612-1631, 2010.
21. Y. Tanaka, L. M. Aleksunes, R. L. Yeager et al., "NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet," Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 655-664, 2008.
22. Y. Tanaka, T. Ikeda, K. Yamamoto,H.Ogawa, and T. Kamisako, "Dysregulated expression of fatty acid oxidation enzymes and iron-regulatory genes in livers of Nrf2-null mice," Journal of Gastroenterology and Hepatology, vol. 27, no. 11, pp. 1711-1717, 2012.
23. Y.-K. J. Zhang, K. C. Wu, J. Liu, and C. D. Klaassen, "Nrf2 deficiency improves glucose tolerance in mice fed a high-fat diet," Toxicology and Applied Pharmacology, vol. 264, no. 3, pp. 305-314, 2012.
24. S. Shin, J. Wakabayashi, M. S. Yates et al., "Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide," European Journal of Pharmacology, vol. 620, no. 1-3, pp. 138-144, 2009.
25. J. Huang, I. Tabbi-Anneni, V. Gunda, and L.Wang, "Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism,"TheAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 299, no. 6, pp. G1211-G1221, 2010.
26. P. K. Saha, V. T. Reddy, M. Konopleva, M. Andreeff, and L. Chan, "The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr-/-mice," The Journal of Biological Chemistry, vol. 285, no. 52, pp. 40581-40592, 2010.
27. C. J. Oh, J.-Y. Kim, A.-K. Min et al., "Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling," Free Radical Biology and Medicine, vol. 52, no. 3, pp. 671-682, 2012.
28. K. Okada, E.Warabi, H. Sugimoto et al., "Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis," Journal of Gastroenterology, vol. 47, no. 8, pp. 924-935, 2012.
29. R. Shimozono, Y. Asaoka, Y. Yoshizawa et al., "Nrf2 activators attenuate the progression of nonalcoholic steatohepatitisrelated fibrosis in a dietary rat models," Molecular Pharmacology, vol. 84, no. 1, pp. 62-70, 2013.
30. A.-L. Levonen, B. G. Hill, E. Kansanen, J. Zhang, and V. M. Darley-Usmar, "Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics," Free Radical Biology andMedicine, vol. 71, pp. 196-207, 2014.
31. A. T. Dinkova-Kostova, W. D. Holtzclaw, and T. W. Kensler, "The role of Keap1 in cellular protective responses," Chemical Research in Toxicology, vol. 18, no. 12, pp. 1779-1791, 2005.
32. T. H. Rushmore, M. R. Morton, and C. B. Pickett, "The antioxidant responsive element: activation by oxidative stress and identification of the DNA consensus sequence required for functional activity," Journal of Biological Chemistry, vol. 266, no. 18, pp. 11632-11639, 1991.
33. W. W. Wasserman and W. E. Fahl, "Functional antioxidant responsive elements," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 5361-5366, 1997.
34. T.Nguyen, P. J. Sherratt, and C. B. Pickett, "Regulatorymechanisms controlling gene expression mediated by the antioxidant response element," Annual Review of Pharmacology and Toxicology, vol. 43, pp. 233-260, 2003.
35. J.-M. Lee, M. J. Calkins, K. Chan, Y.W. Kan, and J. A. Johnson, "Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis," The Journal of Biological Chemistry, vol. 278, no. 14, pp. 12029-12038, 2003.
36. T. W. Kensler, N. Wakabayashi, and S. Biswal, "Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway," Annual Review of Pharmacology and Toxicology, vol. 47, pp. 89-116, 2007.
37. T. Suzuki, H. Motohashi, and M. Yamamoto, "Toward clinical application of the Keap1-Nrf2 pathway," Trends in Pharmacological Sciences, vol. 34, no. 6, pp. 340-346, 2013.
38. E. Kansanen, H.-K. Jyrkkänen, and A.-L. Levonen, "Activation of stress signaling pathways by electrophilic oxidized and nitrated lipids," Free Radical Biology and Medicine, vol. 52, no. 6, pp. 973-982, 2012.
39. P.Rada, A. I. Rojo, S.Chowdhry,M.McMahon, J. D. Hayes, and A. Cuadrado, "SCF/β-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner," Molecular and Cellular Biology, vol. 31, no. 6, pp. 1121-1133, 2011.
40. S. B. Cullinan and J. A. Diehl, "Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway," The International Journal of Biochemistry & Cell Biology, vol. 38, no. 3, pp. 317-332, 2006.
41. W. Miao, L. Hu, P. J. Scrivens, and G. Batist, "Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drugmetabolizing enzymes,"The Journal of Biological Chemistry, vol. 280, no. 21, pp. 20340-20348, 2005.
42. S. Tao, S.Wang, S. J.Moghaddamet al., "Oncogenic KRAS confers chemoresistance by upregulating NRF2," Cancer Research, vol. 74, no. 24, pp. 7430-7441, 2014.
43. J. D. Hayes and A. T. Dinkova-Kostova, "The Nrf2 regulatory network provides an interface between redox and intermediary metabolism," Trends in Biochemical Sciences, vol. 39, no. 4, pp. 199-218, 2014.
44. W. O. Osburn and T. W. Kensler, "Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults," Mutation Research-Reviews in Mutation Research, vol. 659, no. 1-2, pp. 31-39, 2008.
45. H. Malhi and R. J. Kaufman, "Endoplasmic reticulum stress in liver disease," Journal of Hepatology, vol. 54, no. 4, pp. 795-809, 2011.
46. M. Komatsu, H. Kurokawa, S. Waguri et al., "The selective autophagy substrate p62 activates the stress responsive transcription factorNrf2 through inactivation of Keap1," Nature Cell Biology, vol. 12, no. 3, pp. 213-223, 2010.
47. J. Kwon, E. Han, C.-B. Bui et al., "Assurance of mitochondrial integrity and mammalian longevity by the p62-Keap1-Nrf2-Nqo1 cascade," EMBO Reports, vol. 13, no. 2, pp. 150-156, 2012.
48. K. M. Holmstrom, L. Baird, Y. Zhang et al., "Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration," Biology Open, vol. 2, no. 8, pp. 761-770, 2013.
49. M. H. R. Ludtmann, P. R. Angelova, Y. Zhang, A. Y. Abramov, and A. T. Dinkova-Kostova, "Nrf2 affects the efficiency of mitochondrial fatty acid oxidation," Biochemical Journal, vol. 457, no. 3, pp. 415-424, 2014.
50. L. M. Aleksunes and J. E. Manautou, "Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease," Toxicologic Pathology, vol. 35, no. 4, pp. 459-473, 2007.
51. C. D. Klaassen and S. A. Reisman, "Nrf2 the rescue: effects of the antioxidative/electrophilic response on the liver," Toxicology and Applied Pharmacology, vol. 244, no. 1, pp. 57-65, 2010.
52. J. Liu, K. C. Wu, Y.-F. Lu, E. Ekuase, and C. D. Klaassen, "NRF2 protection against liver injury produced by various hepatotoxicants," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 305861, 8 pages, 2013.
53. H. Lu,W. Cui, and C.D. Klaassen, "Nrf2 protects against 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis," Toxicology and Applied Pharmacology, vol. 256, no. 2, pp. 122-135, 2011.
54. W. Xu, C. Hellerbrand, U. A. Kæhler et al., "The Nrf2 transcription factor protects from toxin-induced liver injury and fibrosis," Laboratory Investigation, vol. 88, no. 10, pp. 1068-1078, 2008.
55. S. Silva-Gomes, A. G. Santos, C. Caldas et al., "Transcription factor NRF2 protects mice against dietary iron-induced liver injury by preventing hepatocytic cell death," Journal of Hepatology, vol. 60, no. 2, pp. 354-361, 2014.
56. L.B.M.Tijburg,C.B.Nyathi, G.W.Meijer, andM. J. H. Geelen, "Biosynthesis and secretion of triacylglycerol in rat liver after partial hepatectomy," The Biochemical Journal, vol. 277, no. 3, pp. 723-728, 1991.
57. E. P. Newberry, S. M. Kennedy, Y. Xie et al., "Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models," Hepatology, vol. 48, no. 4, pp. 1097-1105, 2008.
58. I. García-Arcos, P. González-Kother, P. Aspichueta, Y. Rueda, B. Ochoa, and O. Fresnedo, "Lipid analysis reveals quiescent and regenerating liver-specific populations of lipid droplets," Lipids, vol. 45, no. 12, pp. 1101-1108, 2010.
59. T. A. Beyer, W. Xu, D. Teupser et al., "Impaired liver regeneration inNrf2 knockout mice: Role ofROS-mediated insulin/IGF-1 resistance," EMBO Journal, vol. 27, no. 1, pp. 212-223, 2008.
60. R. Dayoub, A. Vogel, J. Schuett et al., "Nrf2 activates augmenter of liver regeneration (ALR) via antioxidant response element and links oxidative stress to liver regeneration," Molecular Medicine, vol. 19, no. 1, pp. 237-244, 2013.
61. F. Sheedfar, S. D. Biase, D. Koonen, and M. Vinciguerra, "Liver diseases and aging: friends or foes?" Aging Cell, vol. 12,no. 6, pp. 950-954, 2013.
62. J. H. Suh, S. V. Shenvi, B. M. Dixon et al., "Decline in transcriptional activity ofNrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid," Proceedings of the NationalAcademy of Sciences of theUnited States ofAmerica, vol. 101, no. 10, pp. 3381-3386, 2004.
63. P.-H. Shih and G.-C. Yen, "Differential expressions of antioxidant status in aging rats: The role of transcriptional factor Nrf2 andMAPK signaling pathway," Biogerontology, vol. 8, no. 2, pp. 71-80, 2007.
64. A.Hirayama, K. Yoh, S. Nagase et al., "EPR imaging of reducing activity in Nrf2 transcriptional factor-deficient mice," Free Radical Biology and Medicine, vol. 34, no. 10, pp. 1236-1242, 2003.
65. A. R. Collins, C. J. Lyon, X. Xia et al., "Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes," Circulation Research, vol. 104, no. 6, pp. e42-e54, 2009.
66. A. A. Gupte, C. J. Lyon, and W. A. Hsueh, "Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis," Current Diabetes Reports, vol. 13, no. 3, pp. 362-371, 2013.
67. R. N. Hardwick, C. D. Fisher, M. J. Canet, A. D. Lake, and N. J. Cherrington, "Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease," DrugMetabolism and Disposition, vol. 38, no. 12, pp. 2293-2301, 2010.
68. H. Sugimoto, K. Okada, J. Shoda et al., "Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice," American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 298, no. 2, pp. G283-G294, 2010.
69. S. Chowdhry, M. H. Nazmy, P. J. Meakin et al., "Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis," Free Radical Biology & Medicine, vol. 48, no. 2, pp. 357-371, 2010.
70. C. Wang, Y. Cui, C. Li et al., "Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet," Lipids in Health and Disease, vol. 12, no. 1, article 165, 2013.
71. K. Okada, E.Warabi, H. Sugimoto et al., "Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet," Journal of Gastroenterology, vol. 48, no. 5, pp. 620-632, 2013.
72. Y. Zhang and G. B. Gordon, "A strategy for cancer prevention: stimulation of the Nrf2-ARE signaling pathway," Molecular CancerTherapeutics, vol. 3, no. 7, pp. 885-893, 2004.
73. A. T. Dinkova-Kostova, C. Abeygunawardana, and P. Talalay, "Chemoprotective properties of phenylpropenoids, bis(benzylidene)cycloalkanones, and related Michael reaction acceptors: correlation of potencies as phase 2 enzyme inducers and radical scavengers," Journal of Medicinal Chemistry, vol. 41, no. 26, pp. 5287-5296, 1998.
74. M. Ramos-Gomez, M.-K. Kwak, P. M. Dolan et al., "Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 6, pp. 3410-3415, 2001.
75. K. Liby, T. Hock, M. M. Yore et al., "The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling," Cancer Research, vol. 65, no. 11, pp. 4789-4798, 2005.
76. K. Iida, K. Itoh, Y. Kumagai et al., "Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis," Cancer Research, vol. 64, no. 18, pp. 6424-6431, 2004.
77. J. Zhao, A. N. Moore, J. B. Redell, and P. K. Dash, "Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury," The Journal of Neuroscience, vol. 27, no. 38, pp. 10240-10248, 2007.
78. M. S. Yates, M.-K. Kwak, P. A. Egner et al., "Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1, 9(11)-dien-28-oyl]imidazole," Cancer Research, vol. 66, no. 4, pp. 2488-2494, 2006.
79. A. M. Bataille and J. E. Manautou, "Nrf2: A potential target for new therapeutics in liver disease," Clinical Pharmacology & Therapeutics, vol. 92, no. 3, pp. 340-348, 2012.
80. S. K. Nelson, S. K. Bose, G. K. Grunwald, P. Myhill, and J. M. McCord, "The induction of human superoxide dismutase and catalase in vivo: A fundamentally new approach to antioxidant therapy," Free Radical Biology and Medicine, vol. 40, no. 2, pp. 341-347, 2006.
81. L.Kappos,R.Gold,D. H.Miller et al., "Efficacy and safety of oral fumarate in patients with relapsing-remittingmultiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study," The Lancet, vol. 372, no. 9648, pp. 1463-1472, 2008.
82. P. E. Pergola, P. Raskin, R. D. Toto et al., "Bardoxolone methyl and kidney function in CKD with type 2 diabetes," The New England Journal of Medicine, vol. 365, no. 4, pp. 327-336, 2011.
83. M. S. Yates, M. Tauchi, F. Katsuoka et al., "Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes," Molecular CancerTherapeutics, vol. 6, no. 1, pp. 154-162, 2007.
84. W.-S. Jeong, Y.-S. Keum, C. Chen et al., "Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells," Journal of Biochemistry and Molecular Biology, vol. 38, no. 2, pp. 167-176, 2005.
85. T. Greco, J. Shafer, and G. Fiskum, "Sulforaphane inhibits mitochondrial permeability transition and oxidative stress," Free Radical Biology andMedicine, vol. 51, no. 12, pp. 2164-2171, 2011.
86. A. Nakamura and Y. Terauchi, "Lessons from mouse models of high-fat diet-induced NAFLD," International Journal of Molecular Sciences, vol. 14, no. 11, pp. 21240-21257, 2013.